Immune checkpoint inhibitors: Significant advancements in non–small cell lung cancer treatment.
- Published in:
- American Journal of Health-System Pharmacy, 2021, v. 78, n. 9, p. 769, doi. 10.1093/ajhp/zxab041
- By:
- Publication type:
- Article
Works by Glode, Ashley E.
Results: 13
1
2
Ublituximab for the treatment of CD20 positive B-cell malignancies.
- Published in:
- Expert Opinion on Investigational Drugs, 2018, v. 27, n. 4, p. 407, doi. 10.1080/13543784.2018.1459560
- By:
- Publication type:
- Article
3
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 686, doi. 10.1177/10781552211073575
- By:
- Publication type:
- Article
4
Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
- Published in:
- Journal of Oncology Pharmacy Practice, 2020, v. 26, n. 8, p. 1964, doi. 10.1177/1078155220938847
- By:
- Publication type:
- Article
5
Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
- Published in:
- Journal of Oncology Pharmacy Practice, 2020, v. 26, n. 6, p. 1369, doi. 10.1177/1078155219895312
- By:
- Publication type:
- Article
6
Apalutamide: A new agent in the management of prostate cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 8, p. 1968, doi. 10.1177/1078155219864424
- By:
- Publication type:
- Article
7
Tailoring Distress Screening in Oncology Populations: Timing distress screening in surgically resectable esophageal cancer.
- Published in:
- Oncology Issues, 2021, v. 36, n. 5, p. 30, doi. 10.1080/10463356.2021.1955592
- By:
- Publication type:
- Article
8
Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.
- Published in:
- Cancer Management & Research, 2016, v. 8, p. 49, doi. 10.2147/CMAR.S81425
- By:
- Publication type:
- Article
9
Review of Biosimilars and Their Potential Use in Oncology Treatment and Supportive Care in the United States.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 133
- By:
- Publication type:
- Article
10
Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control Costs.
- Published in:
- Pharmacotherapy, 2017, v. 37, n. 1, p. 85, doi. 10.1002/phar.1867
- By:
- Publication type:
- Article
11
Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
- Published in:
- Pharmacotherapy, 2016, v. 36, n. 1, p. 99, doi. 10.1002/phar.1687
- By:
- Publication type:
- Article
12
Heart Failure Caused by Molecularly Targeted Therapies for Cancer.
- Published in:
- Pharmacotherapy, 2011, v. 31, n. 1, p. 62, doi. 10.1592/phco.31.1.62
- By:
- Publication type:
- Article
13
Bendamustine: A New Treatment Option for Chronic Lymphocytic Leukemia.
- Published in:
- Pharmacotherapy, 2009, v. 29, n. 11, p. 1375, doi. 10.1592/phco.29.11.1375
- By:
- Publication type:
- Article